Stagnation of Business Investment Due to Difficulty Raising Funds
First written in FY2017. 12 of 21 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2025: 6 of 12 companies on the "Worse" side.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020, the 18th series in September 2021 and the 19th series in March 2023. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Although cash outflows from operating activities continue, the Company continues to believe that there are no concerns regarding cash management for the foreseeable future, against the backdrop of financing through stock acquisition rights issued in the past and other sources. - FY2025-H1RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020, the 18th series in September 2021 and the 19th series in March 2023. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
The Company continues to believe that there are no concerns regarding cash management for the foreseeable future, against the backdrop of financing through stock acquisition rights issued in the past and other sources, while cash outflows from operating activities continue. - FY2024-Q2RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, including optimizing the manufacturing structure in the cell-processing business segment, as well as raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020, the 18th series in September 2021 and the 19th series in March 2023. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of structural reforms and financing through the 14th to 19th series of stock acquisition rights, the Company continues to believe that it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2024-Q1MitigatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, including optimizing the manufacturing structure in the cell-processing business segment, as well as raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020, the 18th series in September 2021 and the 19th series in March 2023. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of financing including the 19th series of stock acquisition rights and structural reforms, the Company continues to believe that it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2023RestatedAnnual report
「However, cash flow from operating activities was negative in the fiscal year, and depending on the future financial position, operating results and cash flow position of the Company, as well as financial market conditions, the Company may have difficulty raising funds.」
The Company continues to disclose that, while cash outflows from operating activities continue, future difficulty raising funds could prevent research and development and capital investment from progressing. - FY2023-Q3RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020, the 18th series in September 2021 and the 19th series in March 2023. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of financing including the 19th series of stock acquisition rights and structural reforms, the Company continues to believe that it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2023-Q2RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020, the 18th series in September 2021 and the 19th series in March 2023. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of financing including the 19th series of stock acquisition rights and funds secured through structural reforms, the Company continues to believe that it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2023-Q1RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020 and the 18th series in September 2021. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of structural reforms and financing through stock acquisition rights issued in the past, the Company continues to believe that it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2022MitigatedAnnual report
「After comprehensively reviewing the Company's cash position at the end of the fiscal year, the Company believes that there is no doubt about the continuity of its business activities and that no significant uncertainty exists regarding the going-concern assumption.」
Although cash flow from operating activities was negative, the Company secured ¥4,499 million in cash and cash equivalents and believes that it has secured sufficient funds required for cash management for the foreseeable future. - FY2022-Q3MitigatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020 and the 18th series in September 2021. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
The Company continues to believe that there are no concerns regarding cash management for the foreseeable future, including in light of the full exercise of the 18th series of stock acquisition rights and the increase in cash and deposits. - FY2022-Q2RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020 and the 18th series in September 2021. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of structural reforms and financing through the 14th to 18th series of stock acquisition rights, the Company continues to believe that it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2022-Q1RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products and other purposes through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020, the 17th series in September 2020 and the 18th series in September 2021. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
The Company continues to believe that, against the backdrop of financing including the 18th series of stock acquisition rights and structural reforms, it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2021-Q3RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020 and the 17th series in September 2020. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of structural reforms and financing through the 14th to 17th series of stock acquisition rights, the Company continues to believe that there are no concerns regarding cash management for the foreseeable future. - FY2021-Q2RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020 and the 17th series in September 2020. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
Against the backdrop of structural reforms and financing through the 14th to 17th series of stock acquisition rights, the Company continues to believe that it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2021-Q1MitigatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June 2019, the 16th series in July 2020 and the 17th series in September 2020. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
The Company continues to explain that, against the backdrop of financing including the 17th series of stock acquisition rights and funds secured through structural reforms, it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2020-Q3MitigatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June 2019 and the 16th series in July 2020. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
The Company stated that, against the backdrop of structural reforms and financing through the 14th, 15th and 16th series of stock acquisition rights, it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2020-Q1RestatedAnnual report
「Under the current circumstances, the Company is maintaining a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June 2019. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
The Company continues to explain that, against the backdrop of structural reforms and financing through stock acquisition rights, it has a stable cash position and no concerns regarding cash management for the foreseeable future. - FY2019-Q3MitigatedAnnual report
「Under the current circumstances, the Company expects to maintain a stable cash position through securing funds by steadily implementing structural reforms, as well as raising funds for the development of regenerative medicine products through the issuance of the 14th and 15th series of stock acquisition rights in June this year. Accordingly, the Company believes that there are no concerns regarding cash management for the foreseeable future.」
The Company indicates that, based on funds secured through structural reforms and the financing obtained through the 14th and 15th series of stock acquisition rights, there are no concerns regarding cash management for the foreseeable future. - FY2019-Q1MitigatedAnnual report
「The Company is working to improve operating cash flow through the steady implementation of the structural reforms and believes that no significant uncertainty exists regarding the going-concern assumption because it expects to secure sufficient working capital for the future.」
The Company continues to address the risk of business stagnation due to difficulty raising funds by indicating that structural reforms are improving operating cash flow and that working capital is expected to be secured. - FY2018-Q2MitigatedAnnual report
「The Company is working to improve operating cash flow through the steady implementation of the structural reforms and believes that no significant uncertainty exists regarding the going-concern assumption because it expects to secure sufficient working capital for the future.」
The Company explains its response to the risk of business investment stagnating due to difficulty raising funds, based on the implementation of structural reforms and the prospect of securing working capital. - FY2017First statedAnnual report
「Cash flow from operating activities was negative during the consolidated fiscal year, and depending on the Group’s future financial position, operating results and cash flows, as well as financial market conditions, it may become difficult to raise funds. In that event, the development of cell therapy products and capital investment in cell culture and processing facilities may not proceed as planned, which could affect the Group’s business activities.」
The Company discloses that difficulty in raising funds while operating cash flow is negative could delay product development and facility investment.